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Summary
 
Agents that restore vascular patency in stroke also increase the risk of intracerebral hemorrhage
(ICH). As Factor IXa is a key intermediary in the intrinsic pathway of coagulation, targeted in-
hibition of Factor IXa–dependent coagulation might inhibit microvascular thrombosis in stroke
without impairing extrinsic hemostatic mechanisms that limit ICH. A competitive inhibitor of
native Factor IXa for assembly into the intrinsic Factor X activation complex, Factor IXai, was
prepared by covalent modification of the Factor IXa active site. In a modified cephalin clotting
time assay, in vivo administration of Factor IXai caused a dose-dependent increase in time to
clot formation (3.6-fold increase at the 300 
 
m
 
g/kg dose compared with vehicle-treated control
animals,
 
 P 
 
, 
 
0.05). Mice given Factor IXai and subjected to middle cerebral artery occlusion
and reperfusion demonstrated reduced microvascular fibrin accumulation by immunoblotting
and immunostaining, reduced 
 
111
 
In-labeled platelet deposition (42% decrease,
 
 P 
 
, 
 
0.05), in-
creased cerebral perfusion (2.6-fold increase in ipsilateral blood flow by laser doppler,
 
 P 
 
,
 
0.05), and smaller cerebral infarcts than vehicle-treated controls (70% reduction,
 
 P 
 
, 
 
0.05)
based on triphenyl tetrazolium chloride staining of serial cerebral sections. At therapeutically ef-
fective doses, Factor IXai was not associated with increased ICH, as opposed to tissue plasmino-
gen activator (tPA) or heparin, both of which significantly increased ICH. Factor IXai was
cerebroprotective even when given after the onset of stroke, indicating that microvascular
thrombosis continues to evolve (and may be inhibited) even after primary occlusion of a major
cerebrovascular tributary.
Key words: Factor IX • thrombosis • anticoagulation • intrinsic coagulation pathway • 
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T
 
imely reestablishment of blood flow to ischemic brain
using thrombolytic agents represents the current treat-
ment paradigm for acute stroke (1–3). However, this ap-
proach is limited by an increased risk of intracerebral hem-
orrhage (ICH)
 
1
 
 and an increase in early mortality (1–5).
Furthermore, even if the best available agent, recombinant
tissue plasminogen activator (tPA), is given promptly,
within 3 h of symptom onset, there is no improvement in
overall mortality (1–3, 5). Even though there is an im-
provement in the composite end point of death and mor-
bidity with tPA treatment, it is likely that efficacy could be
substantially improved if the risk of ICH were lowered. In
addition, recent reports indicate that tPA may have a direct
role in neuronal injury in the setting of stroke (6–11). Lim-
ited anticoagulant trials of heparin in stroke showed hep-
arin to be ineffective and/or associated with an unaccept-
ably high incidence of hemorrhagic conversion (12–17). In
a murine model of stroke, a platelet glycoprotein IIb/IIIa
receptor antagonist, although effective at reducing cerebral
infarct volumes, caused a dose-dependent increase in ICH
(18). Consequently, there remains a clear need to identify
new agents that can promote reperfusion without increas-
ing the risk of ICH.
After an ischemic event, the vascular wall is modified
 
1
 
Abbreviations used in this paper:
 
 APTT, activated partial thromboplastin
time; CBF, cerebral blood flow; Factor IXai, active site–blocked Factor
IXa; ICH, intracerebral hemorrhage; MCAO, middle cerebral artery oc-
clusion; MCCT, modified cephalin clotting time; tPA, tissue plasmino-
gen activator; TTC, triphenyl tetrazolium chloride. 
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from its quiescent, antiadhesive, antithrombotic state to one
which promotes leukocyte adhesion and thrombosis. In
acute stroke, active recruitment of leukocytes by adhesion
receptors expressed in the ipsilateral microvasculature, such
as intercellular adhesion molecule 1 (ICAM-1 [19]) and
P-selectin (20), potentiates postischemic hypoperfusion. How-
ever, experiments with mice deletionally mutant for each
of these genes demonstrate that even in their absence, post-
ischemic cerebral blood flow (CBF) returns only partially
to baseline after removal of an intraluminal middle cerebral
artery occluding suture. These observations imply the exis-
tence of additional mechanisms responsible for postischemic
cerebrovascular no-reflow, especially the possibility that
local thrombosis occurs at the level of the microvascula-
ture (distal to the site of primary occlusion) in stroke. Fur-
thermore, if the ischemic insult is particularly severe, reflow
continues to worsen over time subsequent to withdrawal of
the occluding suture, suggesting ongoing vascular obstruc-
tive processes (such as de novo thrombosis) in the distal mi-
crovasculature. Recent data in a murine model of stroke
implicate glycoprotein IIb/IIIa receptor–dependent platelet
recruitment as a mechanism which amplifies thrombosis in
the postischemic microvasculature (18).
These observations provide the rationale for identifying
new strategies to selectively limit thrombosis in stroke with-
out increasing ICH. We hypothesized that anticoagulant
strategies that do not impair tissue factor–mediated hemo-
static events might reduce thrombosis in the microvascular
lumen yet not impair the ability of friable postischemic ce-
rebral microvessels to form effective hemostatic plugs to
limit ICH. Heparin or hirudin, both of which interfere
with the final common pathway of coagulation, or throm-
bolytic agents such as tPA, which lyse fibrin, do not offer
the theoretical advantage offered by targeting earlier points
in the coagulation cascade. These experiments test whether
selective blockade of IXa/VIIIa/X activation complex as-
sembly using a competitive inhibitor of Factor IXa (active
site–blocked IXa, Factor IXai) can limit intravascular throm-
bosis while preserving mechanisms of extravascular hemo-
stasis in stroke.
 
Materials and Methods
 
Murine Stroke Model.
 
Transient focal cerebral ischemia was
induced in mice by intraluminal occlusion of the middle cerebral
artery (45 min) and reperfusion (24 h) as reported previously (21).
Serial measurements of relative CBF were recorded via laser dop-
pler flowmetry at previously defined neuroanatomic landmarks
(21), and infarct volumes (percentage of ipsilateral hemisphere)
were determined by planimetric/volumetric analysis of triphenyl
tetrazolium chloride (TTC)-stained serial cerebral sections (21).
 
111
 
Indium-platelet Studies.
 
Platelet accumulation was deter-
mined using 
 
111
 
In-labeled platelets, collected and prepared as de-
scribed previously (22). Immediately before surgery, mice were
given 5 
 
3
 
 10
 
6
 
 
 
111
 
In-labeled platelets intravenously; deposition
was quantified after 24 h as ipsilateral cpm/contralateral cpm.
 
Fibrin Immunoblotting/Immunostaining.
 
The accumulation of
fibrin was measured after killing (of fully heparinized animals) us-
ing immunoblotting/immunostaining procedures that have been
 
recently described and validated (21). Because fibrin is extremely
insoluble, hemispheric brain tissue extracts were prepared by
plasmin digestion, then applied to a standard SDS-polyacrylamide
gel for electrophoresis, followed by immunoblotting using a poly-
clonal rabbit anti–human antibody prepared to gamma-gamma
chain dimers present in cross-linked fibrin which can detect mu-
rine fibrin, with relatively little cross-reactivity with fibrinogen
(22). In additional experiments to localize sites of fibrin accumu-
lation, brains were embedded in paraffin, sectioned, and immu-
nostained using the same antifibrin antibody.
 
Spectrophotometric Hemoglobin Assay and Visual ICH Score.
 
ICH was quantified by a spectrophotometry-based assay which
we have developed and validated (23). In brief, mouse brains
were homogenized, sonicated, and centrifuged, and methemoglo-
bin in the supernatants was converted (using Drabkin’s reagent) to
cyanomethemoglobin, the concentration of which was assessed by
measuring OD at 550 nm. For each experiment, the OD relative
to that obtained from a group of control brains is reported.
 
Preparation and Purification of Human IXa/IXai.
 
Factor IXai
was prepared by applying Proplex (a mixture of human vitamin
K–dependent coagulation factors [Factors II, VII, IX, and X]
supplied by Dr. Roger Lundblad, Baxter, Duarte, CA), reconsti-
tuted in Tris-buffered saline (TBS) containing CaCl
 
2
 
, to a column
of calcium-dependent anti–human Factor IX mAb (CaFIX-1) cou-
pled to Affi-Gel 10 (BioRad Laboratories) equilibrated at 4
 
8
 
C
with TBS containing CaCl
 
2
 
 (0.01 M). After sample application,
the column was washed extensively with TBS containing CaCl
 
2
 
(0.01 M) and NaCl (0.5 M), and Factor IX was subsequently
eluted in Tris-HCl (0.1 M; pH 8.0) containing EDTA (0.03 M).
Minimal residual contaminants were then removed using Q-Seph-
arose Fast Flow chromatography. Factor IX thus purified mi-
grated as a single band on SDS-PAGE in the absence and pres-
ence of mercaptoethanol (10%) with an apparent 
 
M
 
r
 
 of 
 
ø
 
68 kD.
Factor IX was then activated at 37
 
8
 
C by incubation with purified
human Factor XIa (Haematologic Technologies, Inc.) at a 1:1,000
enzyme to substrate ratio in Tris-HCl (0.05 M; pH 7.5) contain-
ing NaCl (0.1 M) and CaCl
 
2
 
 (0.005 M) for 1 h. Purified Factor
IXa migrated as a single band in nonreduced SDS-PAGE gels
(
 
M
 
r
 
 
 
ø 
 
45 kD), and as two bands, corresponding to the heavy and
light chains of Factor IXa
 
b
 
, on reduced gels. The latter material
was reacted with a 100-fold molar excess of dansyl-glu-gly-arg
chloromethylketone (Calbiochem) for 3 h at 37
 
8
 
C, and the mix-
ture was dialyzed overnight at 4
 
8
 
C versus 20,000 volumes of PBS.
The final product, Factor IXai, was devoid of procoagulant activ-
ity, migrated identically to untreated Factor IXa on SDS-PAGE,
and had no effect on the clotting time of plasma initiated by Fac-
tor Xa or thrombin. Factor IXai was used for experiments after
filtration (0.2 
 
m
 
m) and chromatography on DeToxi-gel columns
(Pierce Chemical Co.). These preparations had no detectable LPS
at a protein concentration of 1–2 mg/ml, using the limulus amebo-
cyte assay (Sigma Chemical Co.). For experiments in which Fac-
tor IXai was used, it was given as a single intravenous bolus at the
indicated times and at the indicated doses.
 
Modified Cephalin Clotting Time.
 
Equal volumes of Factor
IX–deficient plasma (American Diagnostica Inc.) and 0.144 g/100
ml celite in 0.05 M barbital buffer (Sigma Chemical Co.) were
combined in silicone-coated glass tubes (Sigma Chemical Co.)
for 2 min at 37
 
8
 
C. To this mixture, an equal volume of 1:16
(vol/vol) cephalin (10 mg/ml; Sigma Chemical Co.) in 0.05 M
barbital buffer was added, followed by a one-half volume of sam-
ple plasma. After the addition of calcium chloride to a final con-
centration of 0.001 M, the time required for clot formation was
determined. 
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Results
 
Using a murine model of middle cerebral artery occlu-
sion (MCAO) with an intraluminal vascular suture, which
is removed after 45 min to initiate reperfusion, the occur-
rence of microvascular thrombosis distal to the site of pri-
mary occlusion was examined. Platelet-rich thrombotic foci
occur within the ischemic cerebral hemisphere, as shown by
experiments in which 
 
111
 
In-labeled platelets were adminis-
tered to mice immediately before ischemia and their accu-
mulation in the ipsilateral hemisphere measured at 24 h. In
animals not subjected to the surgical procedure to create
stroke, the presence of platelets was approximately equal
between the right and left hemispheres, as would be ex-
pected (Fig. 1 A, left bar). However, when animals were
subjected to stroke (and received only saline vehicle for
control), radiolabeled platelets preferentially accumulated
in the ischemic (ipsilateral) hemisphere, compared with sig-
nificantly less deposition in the contralateral (nonischemic)
hemisphere (Fig. 1 A, middle bar). These data support the
occurrence of platelet-rich thrombi in the ischemic terri-
tory. Another line of evidence also supports the occurrence
of microvascular thrombosis in stroke. These data come
from the immunodetection of fibrin, using an antibody
Figure 1. (A) The effect of stroke on the accumulation of radiolabeled platelets, and the inhibitory effects of Factor IXai on platelet accumulation.
111In-labeled platelets were administered either to control animals not subjected to stroke (n 5 4, No Stroke) or to animals immediately before stroke
treated preoperatively with vehicle (n 5 7, Stroke 1 Vehicle) or with Factor IXai (300 mg/kg; n 5 7, Stroke 1 IXai). Platelet accumulation at 24 h is
expressed as the ipsilateral cpm/contralateral cpm. Means 6 SEM are shown. *P , 0.05 vs. No Stroke and vs. Stroke 1 IXai. (B) Accumulation of fibrin
in infarcted cerebral tissue. After 45 min of right MCAO and 24 h of reperfusion, brains were harvested from representative mice which had been treated
before surgery with either vehicle (left lanes) or Factor IXai (300 mg/kg, right lanes). The brains were divided into ipsilateral (R) and contralateral (L)
hemispheres, and plasmin digestion was performed to solubilize accumulated fibrin. Immunoblotting was performed using a primary antibody directed
against a neoepitope expressed on the gamma-gamma chain dimer of cross-linked fibrin. (C) Immunohistochemical identification of sites of fibrin forma-
tion in stroke. Using the same procedures described in B, brains were harvested at 24 h, formalin fixed/paraffin embedded, and fibrin was detected im-
munohistochemically using the antifibrin antibody. Cerebral microvessels, shown in the center of each field, stained prominently for fibrin (sepia) in the
ipsilateral hemisphere of vehicle-treated animals (top right). In contrast, microvessels from the ipsilateral hemisphere of Factor IXai–treated mice rarely
demonstrated intravascular fibrin (bottom right). (D) Effect of Factor IXai on CBF in a murine stroke model. Serial measurements of relative CBF were
made using a laser doppler over precisely defined neuroanatomic landmarks (reference 21), expressed as ipsilateral/contralateral CBF. Experiments were
performed as described in B; n 5 48 for Factor IXai–treated animals (300 mg/kg), n 5 62 for vehicle-treated animals subjected to identical procedures.
Means 6 SEM are shown. *P , 0.05. 
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directed against a neoepitope on the gamma-gamma chain
dimer of cross-linked fibrin. Immunoblots demonstrate a
band of increased intensity in the ipsilateral (right) hemi-
sphere of vehicle-treated animals subjected to focal cerebral
ischemia and reperfusion (Fig. 1 B, Vehicle). To demon-
strate that fibrin accumulation was due to the deposition of
intravascular fibrin (rather than due to nonspecific perme-
ability changes and exposure to subendothelial matrix), fi-
brin immunostaining clearly localized the increased fibrin
to the lumina of ipsilateral intracerebral microvessels (Fig. 1 C,
top panels).
 
 
 
As an in vivo physiological correlate of micro-
vascular thrombosis, relative CBF was measured by laser
doppler during the occlusive period as well as after stroke.
These data (Fig. 1 D, bars labeled Vehicle) show that the
intraluminal suture technique significantly reduces ipsilat-
eral CBF during the occlusive period (Fig. 1 D, middle).
Blood flow remains depressed even 24 h after removing the
intraluminal occluding suture (Fig. 1 D, right), correspond-
ing to the platelet, fibrin immunoblot, and fibrin immuno-
staining data indicating the presence of postischemic micro-
vascular thrombosis.
To help establish a functionally deleterious role of micro-
vascular thrombosis in stroke, experiments were performed
to test the effect of inhibiting assembly of the Factor IXa/
VIIIa/X activation complex
 
 
 
in vivo. This particular strat-
egy was selected based on the hypothesis that inhibition of
Factor IXa participation in coagulation might inhibit intra-
vascular thrombosis yet not impair tissue Factor VIIa/Xa–
mediated extravascular hemostasis (and hence, may not in-
crease ICH at clinically effective doses). An estimate of the
antithrombotic potency of Factor IXai was obtained by
testing mouse plasma in a modified cephalin clotting time
assay (MCCT assay, in which the activity of Factor IXa is a
rate-limiting step in thrombus formation) at timed intervals
after bolus administration of Factor IXai or control agents.
Because of the limited quantity of murine plasma obtained
from each sacrificial bleed, plasma was obtained from indi-
vidual control mice each day this assay was performed
(rather than using pooled plasma). Although MCCT con-
trol values in mice varied slightly from day to day, the ap-
proximate mean control MCCT (for the 15-min postad-
ministration time point) was 150 
 
6 
 
6 s (range 108–200 s).
After administration, Factor IXai demonstrated antithrom-
botic potency similar to heparin, prolonging the time to
clot formation in this assay compared with control animals
that had received a normal saline bolus (Fig. 2 A). The ef-
fect of Factor IXai to prolong clotting time in this assay was
dose dependent (Fig. 2 B). To test the in vivo efficacy of
Factor IXai in the setting of stroke, Factor IXai was admin-
istered to mice immediately before stroke, and effects on
cerebral microvascular thrombosis, infarct volume, and ICH
were examined. When Factor IXai (300 
 
m
 
g/kg) is adminis-
tered to animals before introduction of the intraluminal
occluding suture, there is a significant reduction in the ac-
cumulation of radiolabeled platelets in the ipsilateral hemi-
sphere (Fig. 1 A, right bar), no apparent increase in the ipsi-
lateral accumulation of fibrin (Fig. 1 B, Factor IXai), and
decreased evidence of intravascular fibrin by immunostain-
ing (Fig. 1 C). In addition, there is a significant increase in
postischemic blood flow by this treatment, albeit not com-
pletely to preischemic levels (Fig. 1 D).
The clinical relevance of these observations is under-
scored by the striking ability of Factor IXai to reduce cere-
bral infarct volumes (3.3-fold reduction in infarct volumes
Figure 2. MCCT to evaluate the antithrombotic effects of intravenous Factor IXai. (A) Antithrombotic effects of Factor IXai compared with heparin.
Vehicle (n 5 8), Factor IXai (300 mg/kg, n 5 8), or heparin (50 U/kg, n 5 4, or 100 U/kg, n 5 3) was administered to mice as an intravenous bolus, plasma
was obtained at various time points after administration, and the time to clot formation was measured in the MCCT assay described in Materials and
Methods. Relative time to clot formation was determined as the ratio of the time to clot formation of a given experimental condition relative to the
mean time to clot formation of vehicle-treated controls. Means 6 SEM are shown. (B) Dose-dependent antithrombotic effects of Factor IXai. Mice were
given an intravenous single bolus of either vehicle (n 5 8) or Factor IXai at doses of 150 mg/kg (n 5 4), 300 mg/kg (n 5 8), 600 mg/kg (n 5 4), or 1,200
mg/kg (n 5 4), and plasma was obtained at 45 min after administration. Time to clot formation was measured, and data were expressed as in A. *P ,
0.05, ***P , 0.001 vs. vehicle-treated animals. 
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at the 300 
 
m
 
g/kg dose,
 
 P 
 
, 
 
0.05; Fig. 3 A). To test whether
this infarct size-reducing property of Factor IXai was
unique to this compound, or whether a nonspecific anti-
coagulant would also demonstrate efficacy in this regard,
intravenous heparin was also examined at two doses. Only
at the highest dose tested (100 U/kg) did heparin reduce
cerebral infarct volumes; however, this was at the cost of a
significant increase in ICH, measured with a recently vali-
dated spectrophotometric assay (23; Fig. 3 B). In sharp con-
trast, Factor IXai caused an increase in ICH only at the
highest dose tested, but did not do so at doses that demon-
strated striking efficacy to reduce cerebral infarct volumes
(Fig. 3 B). Because a desirable therapeutic agent in stroke
will not only reduce cerebral infarction volumes, but will
also minimize ICH, the data shown in Fig. 3, A and B, are
displayed with infarct volumes plotted along the ordinate
and ICH plotted along the abscissa (Fig. 3 C). As can be
seen in the figure, Factor IXai is able to minimize both in-
farction volumes and ICH (bottom left corner), whereas
only the high dose heparin is able to reduce infarct vol-
umes, but at the cost of increasing ICH.
To compare these results with a current therapy for clin-
ical stroke in humans, tPA, experiments were performed in
which tPA was administered to mice subjected to stroke
and reperfusion. Intravenous tPA at doses of 0.5, 1.0, or 2.0
mg/kg (
 
n
 
 5 
 
6, 11, and 4, respectively) or vehicle (
 
n
 
 5 
 
16)
were administered to mice in the postocclusion period im-
mediately after withdrawal of the occluding suture. Data
were not collected for animals treated with tPA before oc-
clusion because of excessive bleeding associated with the
operative procedure mandated by the stroke model. At the
three doses examined, tPA demonstrated only trends to-
wards reductions in infarct size compared with vehicle-
treated control animals (1.9-, 1.6-, and 1.3-fold reductions
for the 0.5, 1.0, and 2.0 mg/kg doses, respectively); how-
ever, none of these reductions was statistically significant.
On the other hand, administration of tPA at all doses caused
statistically significant increases in ICH (1.7-, 1.4-, and
2.4-fold increases, respectively, for the three doses,
 
 P 
 
5 
 
0.01,
0.03, and 0.002).
 
 
 
Therefore, these data showed no signifi-
cant reductions in cerebral infarction volumes (although
there were trends in this direction) and increased ICH with
tPA. These data are in concordance with the recent report
that tPA given to tPA
 
2
 
/
 
2
 
 or wild-type mice does not im-
prove and may exacerbate cerebral injury in stroke (24).
Because therapies directed at improving outcome from
acute stroke must be given after clinical presentation, and
because fibrin continues to form after the initial ischemic
event in stroke, we tested whether Factor IXai might be ef-
fective when given after initiation of cerebral ischemia.
 
Figure 3.
 
Effect of Factor IXai on infarct volume and ICH in a murine
stroke model. (A) Effect of Factor IXai on cerebral infarct volumes, mea-
sured by TTC staining of serial coronal sections of brain. Before stroke,
animals were given either vehicle (
 
n
 
 5 
 
62), Factor IXai at 150 
 
m
 
g/kg (n 5
5), 300 mg/kg (n 5 48), 600 mg/kg (n 5 6), or 1,200 mg/kg (n 5 6), or
heparin at 50 U/kg (n 5 14) or 100 U/kg (n 5 15). Means 6 SEM are
shown. *P , 0.05 vs. vehicle-treated animals. (B) Effect of Factor IXai on
ICH 24 h after stroke, as measured by a quantitative spectrophotometric
hemoglobin assay (reference 23), in which OD at 550 nm is linearly re-
lated to brain hemoglobin content. Relative OD was determined as the
ratio of the OD of a given experimental condition relative to the mean
OD of vehicle-treated animals. Before stroke, animals were given either
vehicle (n 5 9), Factor IXai at 150 mg/kg (n 5 4), 300 mg/kg (n 5 9),
600 mg/kg (n 5 3), or 1,200 mg/kg (n 5 3), or heparin at 50 U/kg (n 5
5) or 100 U/kg (n 5 11). Means 6 SEM are shown. *P , 0.05 vs. vehi-
cle-treated animals. (C) Infarct volume to ICH plot of data shown in A
and B. Infarct volumes were plotted against ICH to display the effects on
infarct volume and ICH simultaneously for a given agent at specified
doses. V, vehicle; H, heparin; IXai, Factor IXai; doses are shown. Signifi-
cant values are shown in A and B, but are omitted here for clarity.96 Targeted Inhibition of Intrinsic Coagulation Limits Cerebral Injury in Stroke
Factor IXai given after MCAO (after removal of the oc-
cluding suture) provided significant cerebral protection
judged by its ability to significantly reduce cerebral infarc-
tion volumes compared with vehicle-treated controls (Fig. 4).
Discussion
The data in these studies demonstrate clear evidence of
intravascular thrombus formation (both platelets and fibrin)
within the postischemic cerebral microvasculature. In fact,
the ability of an anticoagulant such as Factor IXai to im-
prove outcome even when given after the onset of the re-
perfusion phase suggests that the process of microvascular
thrombosis is not limited to that which occurs during the
major occlusive event. Rather, microvascular thrombosis
appears to be a dynamic process that continues to evolve
even after recanalization of the major vascular tributary.
The pathophysiological relevance of microvascular throm-
bosis in stroke is underscored by the ability of Factor IXai
to reduce microvascular thrombosis (both platelet and fi-
brin accumulation are reduced, with an attendant increase
in postischemic CBF) and to improve stroke outcome. At
clinically relevant doses, treatment with Factor IXai does
not cause an increase in ICH, in sharp contrast to tPA in
this same model of stroke, in which tPA did not signifi-
cantly reduce infarct volumes and also increased the degree
of ICH. These data suggest that selective inhibition of the
Factor IXa/VIIIa/X activation complex assembly with
Factor IXai is a logical target for stroke therapy in humans.
In addition, the potent antithrombotic actions of Factor
IXai are likely to be clinically significant in the setting of
stroke, because Factor IXai reduces infarct volumes even
when given after the onset of stroke.
There are several reasons why targeted anticoagulant
strategies might be superior to the current use of thrombo-
lytic agents in the management of acute stroke, which have
had checkered success in clinical trials. Theoretically, an
ideal treatment for acute stroke would prevent the forma-
tion or induce dissolution of the fibrin-platelet mesh that
causes microvascular thrombosis in the ischemic zone with-
out increasing the risk of ICH. However, thrombolytic
agents that have been studied in clinical trials of acute
stroke have consistently increased the risk of ICH (1–5).
Streptokinase, given in the first several (,6) hours after
stroke onset, was associated with an increased rate of hem-
orrhagic transformation (up to 67%); although there was
increased early mortality, surviving patients suffered less re-
sidual disability. A recent meta-analysis of evidence on
thrombolytic therapy for acute ischemic stroke shows that
when the major tPA trials are considered, there was a 2.99-
fold increase in symptomatic ICH, and when all thrombo-
lytic trials were analyzed, there is a 3.62-fold increase in
symptomatic ICH (5). In addition to the potential increased
hemorrhagic risk with tPA, there is also the risk of thera-
peutic failure; platelets continue to be activated during ad-
ministration of tPA, which may account for some of the
therapeutic failures observed with tPA administration. In
addition, tPA is short-lived, which may limit its usefulness
if microvascular thrombus continues to accrue well beyond
its therapeutic half-life. Although tPA is the best among
available thrombolytic agents in terms of improving mor-
bidity in clinical stroke, there remains the concern that tPA
has been shown to directly mediate excitotoxic neuronal cell
injury via extracellular tPA-catalyzed proteolysis of non-
fibrin substrates (6–11).
Because of the usually precipitous onset of ischemic stroke,
therapy has been targeted primarily towards lysing the ma-
jor fibrinous/atheroembolic debris that occludes a major
vascular tributary to the brain. However, the current work
reinforces the previous observation (18) that there is an im-
portant component of microvascular thrombosis that oc-
curs downstream from the site of original occlusion. This is
likely to be of considerable pathophysiological significance
for postischemic hypoperfusion (no-reflow) and cerebral in-
jury in evolving stroke. These data are in excellent agreement
with those previously reported, in which microthrombi have
been topographically localized to the ischemic region in
fresh brain infarcts (25). These data, along with those in the
current manuscript, show a critical role for platelet accumu-
lation at these downstream sites in cerebral microvascular
thrombosis. It is not surprising that Factor IXai inhibits
platelet accumulation in stroke, because Factor IXa has an
integral role in promoting coagulation via the intrinsic
pathway: Factor IXai competes with native Factor IXa for
assembly into the tenase complex, and therefore causes
competitive inhibition of tenase complex formation. Al-
though this mechanism theoretically should not interfere
directly with platelet adhesion, in vivo, coagulation reac-
tions, platelet activation, and leukocyte recruitment all oc-
cur in close proximity (as well as in proximity to the vessel
wall) and are highly interdependent. This is especially likely
Figure 4. Effect of timing of Factor IXai administration on cerebral in-
farct volumes. Mice were either pretreated with intravenous vehicle (n 5
62) or Factor IXai (300 mg/kg, n 5 48) before focal cerebral ischemia and
reperfusion, or immediately upon withdrawal of the intraluminal middle
cerebral arterial occluding suture (n 5 13 for vehicle, n 5 7 for Factor
IXai). Cerebral infarct volumes were determined from TTC-stained serial
cerebral sections. Means 6 SEM are shown. *P , 0.05 vs. similarly vehi-
cle-treated animals. (The preocclusion administration data are the same
data as those shown in Fig. 3 A for the 300 mg/kg dose, but is repeated
here to facilitate comparison with the postreperfusion data.)97 Choudhri et al.
to be true in cerebral microvessels after ischemia, where
blood flow and dissipation of activated products will be slug-
gish. Therefore, it is likely that local generation of thrombin
(by Factor IXa–dependent coagulation) will locally activate
and recruit platelets, as thrombin is a potent activator of
platelets.
The studies shown here demonstrate that Factor IXa–
mediated coagulation does participate in platelet recruit-
ment, because when Factor IXa–dependent coagulation is
inhibited, platelet recruitment is reduced by nearly half.
Our data do not allow us to extrapolate that initial platelet
activation is the sole cause of postischemic microvascular
thrombosis; rather, it is likely that the phenotype of the en-
dovascular wall changes, perhaps by diminution of nitric
oxide levels, perhaps by tissue factor expression in recruited
mononuclear phagocytes, perhaps by alterations in the fi-
brinolytic balance, all of which lead to a prothrombotic
phenotype. Under these circumstances, even inactivated
platelets passing by may become activated and deposit lo-
cally. Regardless of the relative importance of platelet accu-
mulation versus fibrin formation in the development of mi-
crovascular thrombosis in stroke, the data are clear that the
use of an agent that inhibits assembly of the Factor IXa/
VIIIa/X activation complex represents an effective approach
to limiting thrombosis that occurs within microvascular lu-
mena. In the setting of murine stroke, treatment with Fac-
tor IXai reduces microvascular platelet and fibrin accumu-
lation, improves postischemic CBF, and reduces cerebral
infarct volumes. This approach is even more salient in
stroke because it is effective without impairing extravascu-
lar hemostasis, the maintenance of which may be critical
for preventing ICH.
The potency of Factor IXai as an inhibitor of coagula-
tion stems from the integral role of activated Factor IX
in the coagulation cascade. Patients with hemophilia B
(“Christmas disease”) are deficient in Factor IX and exhibit
hemorrhagic tendencies (26). However, inhibition of Fac-
tor IXa–mediated coagulation may be therapeutically use-
ful in discrete circumstances. For the studies shown here,
active site–blocked Factor IXa was shown to be a competi-
tive inhibitor of Factor IXa–mediated coagulation in vitro
using an MCCT assay instead of the standard activated par-
tial thromboplastin time (APTT). The MCCT assay was
used because the sensitivity of the APTT is not sufficient to
detect the anticoagulant effect of IXai; for example, admin-
istration of Factor IXai (300 mg/kg) did not significantly
alter the APTT (79.9 6 8.9 vs. 70.6 6 8.9 s APTT for IXai-
treated [n 5 7] and vehicle-treated [n 5 4] mice, respec-
tively; P 5 NS). To increase the sensitivity of the standard
APTT, the amount of “phospholipid” (cephalin) in the in-
cubation mixture in the MCCT was decreased; theoreti-
cally, this resulted in a limiting amount of phospholipid.
Using the MCCT, studies showed that increased levels of
IXai prolonged the clotting time in a Factor IXai dose-
dependent manner. The fact that there is a dose-dependent
inhibition of Factor IXa–mediated coagulation by Factor
IXai is not unexpected, because Factor IXai acts as a com-
petitive inhibitor of assembly of the tenase complex. We
would expect that after a point (that at which all Factor IXa
activity is inhibited), we would see no further anticoagulant
effect; however, the in vivo dose–response curves show
that up to a dose of 1,200 mg/kg, we are not at that point.
In addition to its clear-cut efficacy in stroke, active site–
blocked Factor IXa has also been shown to be useful in
several other quite different in vivo models. In cardiopul-
monary bypass, administration of Factor IXai alone (with-
out heparin) was sufficient to maintain patency of the circuit
(27). Factor IXai also appears to be effective at preventing
progressive coronary artery occlusion induced after the ini-
tial application of electric current to the left circumflex cor-
onary artery in dogs (28). This is consistent with the high
thrombotic potency of Factor IXa in a Wessler stasis model
(29). On the other hand, any new therapy for stroke should
be greeted with cautious enthusiasm. Although the thera-
peutic window for Factor IXai is high (doses that increase
ICH are substantially higher than those required for thera-
peutic efficacy), there is a potential for excessive inhibition
of Factor IXa to promote ICH. For instance, protease
nexin-2/amyloid beta protein precursor is a potent inhibi-
tor of Factor IXa which accumulates extensively in the ce-
rebral blood vessels of patients with amyloidosis Dutch-
type with hereditary cerebral hemorrhage and may be a
factor in the development of spontaneous ICH in these pa-
tients (30).
The data that demonstrate that IXai given after the onset
of stroke is effective lead to another interesting hypothesis,
that the formation of thrombus represents a dynamic equi-
librium between the processes of ongoing thrombosis and
ongoing fibrinolysis. Even under normal (nonischemic) set-
tings, this dynamic equilibrium has been shown to occur in
humans (31). The data in the current studies, which show
that Factor IXai is effective even when administered after
the onset of stroke, suggest that this strategy restores the
dynamic equilibrium, which is shifted after cerebral is-
chemia to favor thrombosis, back towards a more quiescent
(antithrombotic) vascular wall phenotype.
As a final consideration, even if thrombolysis successfully
removes the major occluding thrombus, and/or anticoagu-
lant strategies are effective to limit progressive microcircu-
latory thrombosis, blood flow usually fails to return to
preischemic levels. This is exemplified by data in this study,
in which although CBF is considerably improved by Factor
IXai (which limits fibrin/platelet accumulation), CBF still
does not return to preischemic levels. These data support
the existence of multiple effector mechanisms for postischemic
cerebral hypoperfusion, including postischemic neutrophil
accumulation and consequent microvascular plugging with
enhanced P-selectin and ICAM-1 expression by cerebral
microvascular endothelial cells (19, 20). Even when these
adhesion receptors are absent, as is the case in mice dele-
tionally mutant for these receptors, CBF levels are improved
after stroke compared with controls but do not return to
preischemic levels. These data show that both leukocytes
and thrombosis play a role in postischemic cerebral no-
reflow, although the interactions between leukocyte and
platelet recruitment and thrombosis in vivo are likely to be98 Targeted Inhibition of Intrinsic Coagulation Limits Cerebral Injury in Stroke
highly complex, with both positive (32–34) and negative
(35) interactions.
In summary, administration of a competitive inhibitor of
Factor IXa, active site–blocked Factor IXa, represents a novel
therapy for the treatment of stroke. This therapy not only re-
duces microcirculatory thrombosis, improves postischemic
CBF, and reduces cerebral tissue injury after stroke, it can
do so even if given after the onset of cerebral ischemia and
without increasing the risk of ICH. This combination of
infarct size reduction and relatively low downside risk of
ICH makes this an extremely attractive approach for fur-
ther testing and potential clinical trials in human stroke.
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